MX2023003698A - Compuesto biciclico que contiene nitrogeno y pirimidina. - Google Patents
Compuesto biciclico que contiene nitrogeno y pirimidina.Info
- Publication number
- MX2023003698A MX2023003698A MX2023003698A MX2023003698A MX2023003698A MX 2023003698 A MX2023003698 A MX 2023003698A MX 2023003698 A MX2023003698 A MX 2023003698A MX 2023003698 A MX2023003698 A MX 2023003698A MX 2023003698 A MX2023003698 A MX 2023003698A
- Authority
- MX
- Mexico
- Prior art keywords
- nitrogen
- bicyclic compound
- containing bicyclic
- contains pyrimidine
- pyrimidine
- Prior art date
Links
- -1 Nitrogen-containing bicyclic compound Chemical class 0.000 title 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 title 1
- 102100023533 Interleukin-1 receptor-associated kinase 4 Human genes 0.000 abstract 1
- 101710199010 Interleukin-1 receptor-associated kinase 4 Proteins 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/JP2020/037048 WO2022070289A1 (ja) | 2020-09-30 | 2020-09-30 | ピリミジン含有含窒素二環化合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023003698A true MX2023003698A (es) | 2023-06-15 |
Family
ID=80951519
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023003698A MX2023003698A (es) | 2020-09-30 | 2020-09-30 | Compuesto biciclico que contiene nitrogeno y pirimidina. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12590090B2 (https=) |
| EP (1) | EP4223750B1 (https=) |
| JP (1) | JP7433463B2 (https=) |
| KR (1) | KR20230084145A (https=) |
| CN (1) | CN116194454B (https=) |
| AU (1) | AU2020471055B8 (https=) |
| CA (1) | CA3194164A1 (https=) |
| ES (1) | ES3036969T3 (https=) |
| MX (1) | MX2023003698A (https=) |
| PL (1) | PL4223750T3 (https=) |
| WO (1) | WO2022070289A1 (https=) |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110003219A (zh) | 2010-07-13 | 2019-07-12 | 弗·哈夫曼-拉罗切有限公司 | 作为irak4调节剂的吡唑并[1,5a]嘧啶和噻吩并[3,2b]嘧啶衍生物 |
| RU2632900C2 (ru) * | 2010-11-19 | 2017-10-11 | Лиганд Фармасьютикалс Инкорпорейтед | Гетероциклические амины и их применение |
| US9169260B2 (en) * | 2011-03-22 | 2015-10-27 | Merck Sharp & Dohme Corp. | Amidopyrazole inhibitors of interleukin receptor-associated kinases |
| EP2691399B1 (en) | 2011-03-28 | 2016-07-13 | F.Hoffmann-La Roche Ag | Thiazolopyrimidine compounds |
| WO2013042137A1 (en) | 2011-09-19 | 2013-03-28 | Aurigene Discovery Technologies Limited | Bicyclic heterocycles as irak4 inhibitors |
| EP2802590B1 (en) | 2012-01-10 | 2017-03-01 | F. Hoffmann-La Roche AG | Thienopyrimidine compounds |
| CN104169275B (zh) * | 2012-01-13 | 2017-06-09 | 百时美施贵宝公司 | 用作激酶抑制剂的三唑取代的吡啶化合物 |
| RU2548363C2 (ru) | 2012-01-25 | 2015-04-20 | Общество с ограниченной ответственностью "Асинэкс Медхим." | СЕЛЕКТИВНЫЕ ИНГИБИТОРЫ Haspin киназы |
| CN106232122A (zh) | 2013-09-27 | 2016-12-14 | 林伯士艾瑞斯公司 | Irak抑制剂和其用途 |
| DK3126330T3 (en) | 2014-04-04 | 2019-04-23 | Pfizer | BICYCLE-FUSED HETEROARYL OR ARYL COMPOUNDS AND USE THEREOF AS IRAC4 INHIBITORS |
| US9969749B2 (en) | 2014-09-30 | 2018-05-15 | Merck Sharp & Dohme Corp. | Inhibitors of IRAK4 activity |
| US10329294B2 (en) | 2015-03-12 | 2019-06-25 | Merck Sharp & Dohme Corp. | Pyrazolopyrimidine inhibitors of IRAK4 activity |
| CN108473498B (zh) * | 2015-12-22 | 2021-11-02 | 豪夫迈·罗氏有限公司 | 作为IRAK4调节剂的吡唑并[1,5a]嘧啶衍生物 |
| CN106946890A (zh) * | 2017-04-26 | 2017-07-14 | 中国药科大学 | 吡啶类irak4抑制剂、其制备方法及应用 |
| AU2018346051B2 (en) * | 2017-10-02 | 2022-11-10 | 1st Biotherapeutics Inc. | Benzothiazol compounds and methods using the same for treating neurodegenerative disorders |
| WO2022070288A1 (ja) * | 2020-09-30 | 2022-04-07 | 旭化成ファーマ株式会社 | 含窒素二環化合物 |
-
2020
- 2020-09-30 MX MX2023003698A patent/MX2023003698A/es unknown
- 2020-09-30 EP EP20956217.2A patent/EP4223750B1/en active Active
- 2020-09-30 WO PCT/JP2020/037048 patent/WO2022070289A1/ja not_active Ceased
- 2020-09-30 KR KR1020237010766A patent/KR20230084145A/ko not_active Ceased
- 2020-09-30 US US18/029,289 patent/US12590090B2/en active Active
- 2020-09-30 CA CA3194164A patent/CA3194164A1/en active Pending
- 2020-09-30 CN CN202080105488.8A patent/CN116194454B/zh active Active
- 2020-09-30 ES ES20956217T patent/ES3036969T3/es active Active
- 2020-09-30 JP JP2022553287A patent/JP7433463B2/ja active Active
- 2020-09-30 PL PL20956217.2T patent/PL4223750T3/pl unknown
- 2020-09-30 AU AU2020471055A patent/AU2020471055B8/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022070289A1 (ja) | 2022-04-07 |
| ES3036969T3 (en) | 2025-09-25 |
| JP7433463B2 (ja) | 2024-02-19 |
| US12590090B2 (en) | 2026-03-31 |
| AU2020471055B8 (en) | 2023-12-21 |
| CN116194454B (zh) | 2025-02-18 |
| PL4223750T3 (pl) | 2025-09-15 |
| EP4223750A4 (en) | 2024-06-19 |
| CA3194164A1 (en) | 2022-04-07 |
| JPWO2022070289A1 (https=) | 2022-04-07 |
| AU2020471055B2 (en) | 2023-12-14 |
| KR20230084145A (ko) | 2023-06-12 |
| CN116194454A (zh) | 2023-05-30 |
| US20240025893A1 (en) | 2024-01-25 |
| EP4223750A1 (en) | 2023-08-09 |
| EP4223750B1 (en) | 2025-06-25 |
| AU2020471055A1 (en) | 2023-05-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021005898A (es) | Terapia de combinacion que incluye un inhibidor de krasg12c y uno o mas agentes farmaceuticamente activos adicionales para el tratamiento de canceres. | |
| MX2023000693A (es) | Inhibidor de egfr. | |
| ECSP20035590A (es) | Derivado de oxi-fluoropiperidina como inhibidor de quinasa | |
| CL2020001754A1 (es) | Derivado de amino-fluoropiperidina como inhibidor de quinasa. | |
| MX2016013908A (es) | Novedoso compuesto de 1,2,4-triazina disustituida. | |
| MX2018010176A (es) | Compuesto novedoso de pirimidina condensada o sal del mismo. | |
| CL2022000763A1 (es) | Derivados de 2-isoindol-1,3,4-oxadiazol útiles como inhibidores de la histona desacetilasa 6 (hdac6) | |
| MX2018002889A (es) | Compuesto de pirimidina fusionada o sal del mismo. | |
| CL2018003260A1 (es) | Compuestos de bencenosulfonamida y sus usos como agentes terapéuticos. | |
| EA201691058A1 (ru) | Производные пирролопирролона и их применение для лечения заболеваний | |
| MX384072B (es) | Compuesto derivado de pirrolo-piridina, metodo para preparar el mismo y composicion farmaceutica que contiene el mismo como ingrediente activo para la prevencion o el tratamiento de enfermedades relacionadas con la proteina cinasa. | |
| NZ758449A (en) | Heteroaromatic compounds useful in therapy | |
| MX2022006333A (es) | Compuesto triheterociclico como inhibidor de jak y uso del mismo. | |
| PE20210123A1 (es) | Compuesto de anillo de metillactama y uso farmaceutico del mismo | |
| ZA202309001B (en) | Abhd6 antagonist | |
| MX2021008213A (es) | Derivados de (2,5-dioxopirrolidina-1-il)(fenil)-acetamida y su uso en el tratamiento de enfermedades neurologicas. | |
| BR112020026014A8 (pt) | Derivado de lactama condensado | |
| MX2018009458A (es) | Derivado de sulfonamida heterociclico y medicina que contiene el mismo. | |
| DOP2019000194A (es) | Derivados de pirrolotriazina como inhibidor de cinasas | |
| MX2022008148A (es) | Inhibidores de btk. | |
| CO2019013254A2 (es) | Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias | |
| MY197518A (en) | Preventive and/or therapeutic agent of immune disease | |
| MX2023003698A (es) | Compuesto biciclico que contiene nitrogeno y pirimidina. | |
| MX2023003690A (es) | Compuesto macrociclico. | |
| MX2019010967A (es) | Agente terapeutico o profilactico para neuropatias perifericas. |